HU227742B1
(en)
*
|
1996-10-18 |
2012-02-28 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
GB9707659D0
(en)
*
|
1997-04-16 |
1997-06-04 |
Peptide Therapeutics Ltd |
Hepatitis C NS3 Protease inhibitors
|
US6767991B1
(en)
|
1997-08-11 |
2004-07-27 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptides
|
WO1999007734A2
(fr)
*
|
1997-08-11 |
1999-02-18 |
Boehringer Ingelheim (Canada) Ltd. |
Analogues de peptides inhibiteurs de l'hepatite c
|
EP1003775B1
(fr)
*
|
1997-08-11 |
2005-03-16 |
Boehringer Ingelheim (Canada) Ltd. |
Peptides inhibiteurs de l'hepatite c
|
GB9806815D0
(en)
*
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
EP1066247B1
(fr)
*
|
1998-03-31 |
2006-11-22 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de serine protease, particulierement de la protease ns3 du virus de l'hepatite c
|
GB9809664D0
(en)
|
1998-05-06 |
1998-07-01 |
Hoffmann La Roche |
a-Ketoamide derivatives
|
GB9812523D0
(en)
*
|
1998-06-10 |
1998-08-05 |
Angeletti P Ist Richerche Bio |
Peptide inhibitors of hepatitis c virus ns3 protease
|
AR022061A1
(es)
*
|
1998-08-10 |
2002-09-04 |
Boehringer Ingelheim Ca Ltd |
Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
EP1159273A1
(fr)
|
1999-03-02 |
2001-12-05 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
UA74546C2
(en)
*
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
WO2001002601A2
(fr)
*
|
1999-07-07 |
2001-01-11 |
Du Pont Pharmaceuticals Company |
Systemes de dosage cellulaire destines a l'examen de l'activite de la protease ns3 hcv
|
US7122627B2
(en)
|
1999-07-26 |
2006-10-17 |
Bristol-Myers Squibb Company |
Lactam inhibitors of Hepatitis C virus NS3 protease
|
EP1206449A1
(fr)
*
|
1999-07-26 |
2002-05-22 |
Bristol-Myers Squibb Company |
Inhibiteurs lactame de la protease ns3 du virus de l'hepatite c
|
US6420364B1
(en)
|
1999-09-13 |
2002-07-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compound useful as reversible inhibitors of cysteine proteases
|
US7026469B2
(en)
|
2000-10-19 |
2006-04-11 |
Wake Forest University School Of Medicine |
Compositions and methods of double-targeting virus infections and cancer cells
|
EP1252178A1
(fr)
*
|
1999-12-03 |
2002-10-30 |
Bristol-Myers Squibb Pharma Company |
Inhibiteurs d'alpha-cetoamides de la protease ns3 du virus de l'hepatite c
|
EP1235802B1
(fr)
*
|
1999-12-07 |
2005-07-13 |
Theravance, Inc. |
Derives de carbamate presentant une activite antagoniste du recepteur muscarinique
|
CA2396504A1
(fr)
*
|
2000-02-29 |
2001-09-07 |
Dupont Pharmaceuticals Company |
Inhibiteurs de la protease ns3 du virus de l'hepatite c
|
AU2006202124B2
(en)
*
|
2000-04-03 |
2010-01-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3 Protease
|
DE60111509T2
(de)
*
|
2000-04-03 |
2006-05-11 |
Vertex Pharmaceuticals Inc., Cambridge |
Inhibitoren von Serin-Proteasen, insbesondere der Hepatitis-C-Virus NS23-Protease
|
IL151934A0
(en)
|
2000-04-05 |
2003-04-10 |
Schering Corp |
Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
|
WO2001081325A2
(fr)
|
2000-04-19 |
2001-11-01 |
Schering Corporation |
Inhibiteurs macrocycliques de la protease ns3-serine du virus de l'hepatite c comprenant des fractions p2 alkyle et aryle alanine
|
PE20011350A1
(es)
|
2000-05-19 |
2002-01-15 |
Vertex Pharma |
PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
CZ301182B6
(cs)
|
2000-05-26 |
2009-12-02 |
Idenix (Cayman) Limited |
Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
|
US20020007324A1
(en)
*
|
2000-06-09 |
2002-01-17 |
Centner David J. |
System and method for effectively conducting transactions between buyers and suppliers
|
US7244721B2
(en)
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
US7169760B2
(en)
*
|
2000-07-21 |
2007-01-30 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
AR034127A1
(es)
*
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
RU2355700C9
(ru)
*
|
2000-07-21 |
2010-03-20 |
Шеринг Корпорейшн |
Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
AU2002218133A1
(en)
*
|
2000-10-12 |
2002-04-22 |
Viromics Gmbh |
Agents for the treatment of viral infections
|
PT1411954E
(pt)
|
2000-10-18 |
2011-03-16 |
Pharmasset Inc |
Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
MXPA03005219A
(es)
|
2000-12-12 |
2003-09-25 |
Schering Corp |
Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
|
WO2002048157A2
(fr)
*
|
2000-12-13 |
2002-06-20 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones et leurs derives associes, utiles en tant qu'inhibiteurs des proteases ns3 du virus de l'hepatite c
|
US6653295B2
(en)
|
2000-12-13 |
2003-11-25 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
ES2532836T3
(es)
|
2001-01-22 |
2015-04-01 |
Merck Sharp & Dohme Corp. |
Derivados de nucleósidos como inhibidores de la ARN polimerasa viral dependiente de ARN
|
CN100402549C
(zh)
|
2001-07-11 |
2008-07-16 |
沃泰克斯药物股份有限公司 |
桥连二环的丝氨酸蛋白酶抑制剂
|
WO2003035060A1
(fr)
*
|
2001-10-24 |
2003-05-01 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de la serine protease, en particulier de la protease ns3-ns4a du virus de l'hepatite c, integrant un systeme de cycles accoles
|
MY151199A
(en)
*
|
2001-11-02 |
2014-04-30 |
Rigel Pharmaceuticals Inc |
Substituted diphenyl heterocycles useful for treating hcv infection
|
DE60329367D1
(de)
|
2002-01-23 |
2009-11-05 |
Schering Corp |
Verwendung bei der bekämpfung von hepatitis c virusinfektion
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
TW200403236A
(en)
|
2002-04-11 |
2004-03-01 |
Vertex Pharma |
Inhibitors or serine proteases, particularly HCV NS3-NS4A protease
|
MY140680A
(en)
*
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
WO2003099316A1
(fr)
|
2002-05-20 |
2003-12-04 |
Bristol-Myers Squibb Company |
Sulfamides heterocycliques en tant qu'inhibiteurs du virus de l'hepatite c
|
JP4312718B2
(ja)
*
|
2002-05-20 |
2009-08-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
AU2003301959A1
(en)
|
2002-05-20 |
2004-06-03 |
Bristol-Myers Squibb Company |
Substituted cycloalkyl p1' hepatitis c virus inhibitors
|
ES2469569T3
(es)
|
2002-06-28 |
2014-06-18 |
Idenix Pharmaceuticals, Inc. |
Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae
|
AU2003277891A1
(en)
*
|
2002-09-23 |
2004-04-08 |
Medivir Ab |
Hcv ns-3 serine protease inhibitors
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
HUE033832T2
(en)
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
EP1613620A1
(fr)
|
2003-04-11 |
2006-01-11 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc
|
CN100453553C
(zh)
*
|
2003-04-11 |
2009-01-21 |
沃泰克斯药物股份有限公司 |
丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
|
AU2011203054B2
(en)
*
|
2003-04-11 |
2012-04-26 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
|
US7326790B2
(en)
|
2003-05-02 |
2008-02-05 |
Rigel Pharmaceuticals, Inc. |
Diphenylisoxazole compounds and hydro isomers thereof
|
CN103204903A
(zh)
|
2003-05-21 |
2013-07-17 |
贝林格尔.英格海姆国际有限公司 |
丙型肝炎抑制剂化合物
|
EP3521297B1
(fr)
|
2003-05-30 |
2021-12-22 |
Gilead Pharmasset LLC |
Analogues de nucléoside fluorés modifiés
|
PE20050251A1
(es)
*
|
2003-07-18 |
2005-04-13 |
Vertex Pharma |
Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc
|
EP1658302B1
(fr)
|
2003-07-25 |
2010-08-25 |
IDENIX Pharmaceuticals, Inc. |
Analogues des nucleosides puriques pour traiter flaviviridae et notamment l'hepatite c
|
US7576206B2
(en)
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
MXPA06002250A
(es)
|
2003-08-26 |
2006-05-17 |
Schering Corp |
Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c.
|
AR045596A1
(es)
*
|
2003-09-05 |
2005-11-02 |
Vertex Pharma |
Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
|
CA2538791A1
(fr)
*
|
2003-09-18 |
2005-03-31 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
|
ATE500264T1
(de)
|
2003-09-22 |
2011-03-15 |
Boehringer Ingelheim Int |
Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
|
ATE497505T1
(de)
|
2003-09-26 |
2011-02-15 |
Schering Corp |
Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
|
WO2005037860A2
(fr)
*
|
2003-10-10 |
2005-04-28 |
Vertex Pharmaceuticals Incoporated |
Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv
|
MXPA06003963A
(es)
|
2003-10-14 |
2006-08-25 |
Intermune Inc |
Acidos carboxilicos macrociclicos y acilsulfonamidas como inhibidores de replicacion del hcv.
|
EP1944042A1
(fr)
|
2003-10-27 |
2008-07-16 |
Vertex Pharmceuticals Incorporated |
Combinaisons pour le traitement HCV
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
JP4890254B2
(ja)
|
2003-10-27 |
2012-03-07 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Hcvns3−ns4aプロテアーゼ耐性突然変異体
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7253160B2
(en)
|
2003-11-20 |
2007-08-07 |
Schering Corporation |
Depeptidized inhibitors of hepatitis C virus NS3 protease
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
EP1730167B1
(fr)
|
2004-01-21 |
2011-01-12 |
Boehringer Ingelheim International GmbH |
Peptides macrocycliques actifs contre le virus de l'hepatite c
|
ES2336009T3
(es)
*
|
2004-01-30 |
2010-04-07 |
Medivir Ab |
Inhibidores de la ns-3 serina proteasa del vhc.
|
EP2311851A3
(fr)
|
2004-02-04 |
2011-05-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitoren der Serinproteasen, insbesondere der HCV-NS3-NS4A-Protease
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
ES2322602T3
(es)
|
2004-02-24 |
2009-06-23 |
Japan Tobacco, Inc. |
Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc.
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
DE602005015093D1
(de)
|
2004-02-27 |
2009-08-06 |
Schering Corp |
Neue verbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
|
AU2005219859A1
(en)
|
2004-02-27 |
2005-09-15 |
Schering Corporation |
Inhibitors of hepatitis C virus NS3 protease
|
EP1748983A2
(fr)
|
2004-02-27 |
2007-02-07 |
Schering Corporation |
Nouveaux composes en tant qu'inhibiteurs de la protease serine ns3 du virus de l'hepatite c
|
MY145081A
(en)
|
2004-02-27 |
2011-12-15 |
Schering Corp |
Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
|
WO2005090334A2
(fr)
*
|
2004-03-12 |
2005-09-29 |
Vertex Pharmaceuticals Incorporated |
Procedes et produits intermediaires
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
PT1745064E
(pt)
|
2004-04-15 |
2011-03-23 |
Proteolix Inc |
Compostos para a inibição de uma enzima de proteassoma
|
BRPI0510802A
(pt)
*
|
2004-05-10 |
2007-11-06 |
Proteolix Inc |
compostos para inibição de enzima
|
CA2566610A1
(fr)
|
2004-05-20 |
2005-12-01 |
Schering Corporation |
Prolines substituees en tant qu'inhibiteurs de la serine protease du virus ns3 de l'hepatite c
|
BRPI0513426A
(pt)
|
2004-07-16 |
2007-11-27 |
Gilead Sciences Inc |
processo de preparação de amino ácidos úteis na preparação de moduladores de receptores de peptìdeos
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
EP1771454B1
(fr)
|
2004-07-20 |
2011-06-15 |
Boehringer Ingelheim International GmbH |
Analogues peptidiques inhibiteurs de l'hepatite c
|
WO2006020580A2
(fr)
*
|
2004-08-09 |
2006-02-23 |
Alios Biopharma Inc. |
Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation
|
US7597884B2
(en)
*
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
CN101068828A
(zh)
|
2004-08-27 |
2007-11-07 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物
|
RU2433124C2
(ru)
|
2004-09-14 |
2011-11-10 |
Фармассет, Инк. |
Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
|
WO2006039488A2
(fr)
|
2004-10-01 |
2006-04-13 |
Vertex Pharmaceuticals Incorporated |
Inhibition de la protease ns3-ns4a du vhc
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7468383B2
(en)
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
NZ563909A
(en)
|
2005-05-13 |
2011-10-28 |
Virochem Pharma Inc |
Thiophene derivatives and their use for the treatment or prevention of flavivirus infections
|
WO2006127289A1
(fr)
*
|
2005-05-20 |
2006-11-30 |
Valeant Research & Development |
Traitement de l'hepatite c (hcv) au moyen de doses sous-therapeutiques de ribavirine
|
WO2006130686A2
(fr)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Administration d'inhibiteurs de protease du vhc en combinaison avec des aliments pour ameliorer la biodisponibilite
|
US20060276404A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
NZ563365A
(en)
|
2005-06-02 |
2011-02-25 |
Schering Corp |
Combination of HCV protease inhibitors with a surfactant
|
US20070237818A1
(en)
*
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
BRPI0613142A2
(pt)
|
2005-06-17 |
2010-12-21 |
Novartis Ag |
uso de sangliferina em hcv
|
US7608592B2
(en)
*
|
2005-06-30 |
2009-10-27 |
Virobay, Inc. |
HCV inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2007015824A2
(fr)
|
2005-07-25 |
2007-02-08 |
Intermune, Inc. |
Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l’hépatite c
|
KR101381387B1
(ko)
|
2005-07-29 |
2014-04-11 |
메디비르 아베 |
C형 간염 바이러스의 마크로사이클릭 억제제
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
RS52058B
(en)
|
2005-07-29 |
2012-04-30 |
Tibotec Pharmaceuticals |
MACROCYCLIC HEPATITIS VIRUS INHIBITORS C
|
BRPI0614638A2
(pt)
|
2005-07-29 |
2011-04-12 |
Tibotec Pharm Ltd |
compostos inibidores macrocìclicos do vìrus da hepatite c, uso dos mesmos, processo para a preparação dos mesmos, combinação e composição farmacêutica
|
TWI383980B
(zh)
|
2005-07-29 |
2013-02-01 |
Tibotec Pharm Ltd |
C型肝炎病毒之大環抑制劑
|
PE20070210A1
(es)
|
2005-07-29 |
2007-04-16 |
Tibotec Pharm Ltd |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
TWI382025B
(zh)
|
2005-07-29 |
2013-01-11 |
Tibotec Pharm Ltd |
C型肝炎病毒之大環抑制劑(四)
|
JO2768B1
(en)
|
2005-07-29 |
2014-03-15 |
تيبوتيك فارماسيوتيكالز ليمتد |
Large cyclic inhibitors of hepatitis C virus
|
CN101273052B
(zh)
|
2005-07-29 |
2016-01-13 |
爱尔兰詹森科学公司 |
丙型肝炎病毒的大环抑制剂
|
WO2007016476A2
(fr)
*
|
2005-08-01 |
2007-02-08 |
Phenomix Corporation |
Inhibiteurs de la sérine protéase de l'hépatite c et emploi desdits inhibiteurs
|
AU2006275413B2
(en)
|
2005-08-02 |
2012-07-19 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
CN101291909B
(zh)
|
2005-08-19 |
2012-09-05 |
弗特克斯药品有限公司 |
方法和中间体
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
WO2007044893A2
(fr)
|
2005-10-11 |
2007-04-19 |
Intermune, Inc. |
Composés et méthodes pour l'inhibition de la réplication du virus de l'hépatite c
|
WO2007047146A2
(fr)
*
|
2005-10-11 |
2007-04-26 |
Intermune, Inc. |
Inhibiteurs de réplication virale
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
NZ595196A
(en)
|
2005-11-09 |
2013-03-28 |
Proteolix Inc |
Peptide-based compounds for enzyme inhibition
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
KR20140098867A
(ko)
|
2005-11-11 |
2014-08-08 |
버텍스 파마슈티칼스 인코포레이티드 |
C형 간염 바이러스 변이체
|
UA96283C2
(uk)
*
|
2005-12-23 |
2011-10-25 |
Зіланд Фарма А/С |
Модифіковані міметики лізину
|
EP2029153A2
(fr)
*
|
2006-01-27 |
2009-03-04 |
Phenomix Corporation |
Inhibiteurs de la sérine protéase de l'hépatite c et leurs utilisations
|
TW200800265A
(en)
*
|
2006-02-09 |
2008-01-01 |
Schering Corp |
Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
|
WO2007098270A2
(fr)
|
2006-02-27 |
2007-08-30 |
Vertex Pharmaceuticals Incorporated |
Co-cristaux et compositions pharmaceutiques les comprenant
|
BRPI0709567A2
(pt)
*
|
2006-03-16 |
2011-07-12 |
Vertex Pharma |
inibidores deuterados de protease de hepatite c
|
JP5167244B2
(ja)
|
2006-04-11 |
2013-03-21 |
ノバルティス アーゲー |
Hcv/hiv阻害剤およびそれらの使用
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
MX2008014839A
(es)
|
2006-05-23 |
2008-12-05 |
Irm Llc |
Compuestos y composiciones en la forma de inhibidores de proteasa de activacion mediante canal.
|
US7691852B2
(en)
|
2006-06-19 |
2010-04-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
US7935670B2
(en)
|
2006-07-11 |
2011-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1886685A1
(fr)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
|
EP2054076A2
(fr)
*
|
2006-08-21 |
2009-05-06 |
United Therapeutics Corporation |
Polytherapie destinée a traiter des infections virales
|
WO2008027397A2
(fr)
*
|
2006-08-28 |
2008-03-06 |
Vertex Pharmaceuticals Incorporated |
Procédé pour identifier des inhibiteurs de protéases
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
MX2009005185A
(es)
|
2006-11-15 |
2009-07-07 |
Virochem Pharma Inc |
Analogos de tiofeno para el tratamiento o prevencion de infecciones de flavivirus.
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2673111A1
(fr)
|
2006-12-07 |
2008-06-19 |
Schering Corporation |
Formulation de matrice sensible au ph
|
PL2468724T3
(pl)
|
2006-12-21 |
2016-05-31 |
Zealand Pharma As |
Synteza związków pirolidynowych
|
JP5055377B2
(ja)
|
2006-12-22 |
2012-10-24 |
シェーリング コーポレイション |
[5,6−環]環形成インドール誘導体およびその使用方法
|
MX2009006878A
(es)
|
2006-12-22 |
2009-07-07 |
Schering Corp |
Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
|
WO2008082484A1
(fr)
|
2006-12-22 |
2008-07-10 |
Schering Corporation |
Dérivés indoliques annulaires à noyau cyclique à 4 à 5 éléments utilisables pour le traitement ou la prévention des infections par le vhc et autre infections virales associées
|
MX2009008540A
(es)
|
2007-02-08 |
2009-08-18 |
Tibotec Pharm Ltd |
Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
|
KR20090108131A
(ko)
*
|
2007-02-09 |
2009-10-14 |
아이알엠 엘엘씨 |
채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
|
NZ579295A
(en)
|
2007-02-27 |
2012-03-30 |
Vertex Pharma |
Inhibitors of serine proteases
|
AP2009004960A0
(en)
*
|
2007-02-27 |
2009-08-31 |
Vertex Pharma |
Co-crystals and pharmaceutical compositions comprising the same
|
WO2008106167A1
(fr)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
|
AU2008219622A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
AU2008248116A1
(en)
|
2007-05-04 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Combination therapy for the treatment of HCV infection
|
AP2874A
(en)
|
2007-06-29 |
2014-03-31 |
Gilead Sciences Inc |
Antiviral compounds
|
KR20100038417A
(ko)
|
2007-06-29 |
2010-04-14 |
길리애드 사이언시즈, 인코포레이티드 |
항바이러스 화합물
|
KR20100067652A
(ko)
|
2007-08-29 |
2010-06-21 |
쉐링 코포레이션 |
치환된 인돌 유도체 및 이의 사용방법
|
PE20090994A1
(es)
|
2007-08-29 |
2009-08-03 |
Schering Corp |
Derivados de azaindol 2,3-sustituidos como agentes antivirales
|
BRPI0816116A2
(pt)
|
2007-08-29 |
2015-03-03 |
Schering Corp |
Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
|
US8492546B2
(en)
*
|
2007-08-30 |
2013-07-23 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
SG10201902704TA
(en)
|
2007-10-04 |
2019-04-29 |
Onyx Therapeutics Inc |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
EP2222672B1
(fr)
|
2007-11-16 |
2013-12-18 |
Merck Sharp & Dohme Corp. |
Dérivés d'indole à substitution par aminosulfonyle en position 3 et leurs procédés d'utilisation
|
WO2009064848A1
(fr)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
Dérivés d'indole à substitution hétérocyclique en position 3 et leurs procédés d'utilisation
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
NZ587133A
(en)
|
2008-02-04 |
2012-10-26 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitor compounds for treating an HCV infection
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2300491B1
(fr)
|
2008-05-29 |
2016-01-06 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l hépatite c
|
US8901139B2
(en)
|
2008-06-13 |
2014-12-02 |
Merck Sharp & Dohme Corp. |
Tricyclic indole derivatives and methods of use thereof
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
AR072937A1
(es)
|
2008-08-20 |
2010-09-29 |
Schering Corp |
Derivados de piridina y pirimidina sustituida y su uso en el tratamiento de infecciones virales
|
AU2009282574B2
(en)
|
2008-08-20 |
2014-08-21 |
Merck Sharp & Dohme Corp. |
Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
TW201019939A
(en)
|
2008-08-20 |
2010-06-01 |
Schering Corp |
Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
AR072940A1
(es)
|
2008-08-20 |
2010-09-29 |
Schering Corp |
Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP3025727A1
(fr)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Procédés de traitement des maladies du foie
|
EP3090737A1
(fr)
|
2008-10-21 |
2016-11-09 |
Onyx Therapeutics, Inc. |
Thérapie de combinaison avec peptides d'époxycétones
|
CN104163816A
(zh)
|
2008-12-03 |
2014-11-26 |
普雷西迪奥制药公司 |
Hcv ns5a的抑制剂
|
BRPI0922364A2
(pt)
|
2008-12-03 |
2017-08-29 |
Presidio Pharmaceuticals Inc |
Composto, composição farmacêutica e uso de um composto
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8589372B2
(en)
|
2008-12-16 |
2013-11-19 |
Clinton A. Krislov |
Method and system for automated document registration with cloud computing
|
US8914351B2
(en)
|
2008-12-16 |
2014-12-16 |
Clinton A. Krislov |
Method and system for secure automated document registration from social media networks
|
JP2012512878A
(ja)
*
|
2008-12-19 |
2012-06-07 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hcvns3プロテアーゼインヒビター
|
SG172359A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
CL2009002208A1
(es)
|
2008-12-23 |
2010-10-29 |
Gilead Pharmasset Llc |
Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
|
KR20110104074A
(ko)
|
2008-12-23 |
2011-09-21 |
파마셋 인코포레이티드 |
퓨린 뉴클레오시드의 합성
|
US8102720B2
(en)
*
|
2009-02-02 |
2012-01-24 |
Qualcomm Incorporated |
System and method of pulse generation
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス,インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤
|
CN102448458B
(zh)
|
2009-03-18 |
2015-07-22 |
小利兰·斯坦福大学理事会 |
治疗黄病毒科病毒感染的方法和组合物
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
CA2755658A1
(fr)
|
2009-03-27 |
2010-09-30 |
Presidio Pharmaceuticals, Inc. |
Inhibiteurs a noyaux fusionnes de l'hepatite c
|
US8841302B2
(en)
|
2009-04-06 |
2014-09-23 |
Ptc Therapeutics, Inc. |
HCV inhibitor and therapeutic agent combinations
|
WO2010117936A1
(fr)
|
2009-04-06 |
2010-10-14 |
Schering Corporation |
Associations d'un inhibiteur du virus de l'hépatite c (vhc), tels des dérivés pyrroliques bicycliques, et d'un agent thérapeutique
|
CA2758072A1
(fr)
|
2009-04-08 |
2010-10-14 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs macrocycliques de la serine protease
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8980920B2
(en)
|
2009-05-29 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
|
WO2011017389A1
(fr)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de lhépatite c
|
HUE030402T2
(en)
|
2009-09-15 |
2017-05-29 |
Taigen Biotechnology Co Ltd |
HCV protease inhibitors
|
JP5919196B2
(ja)
|
2009-11-13 |
2016-05-18 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
転移抑制のためのペプチドエポキシケトンの使用
|
WO2011063076A1
(fr)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
|
WO2011066241A1
(fr)
|
2009-11-25 |
2011-06-03 |
Schering Corporation |
Composés tricycliques fusionnés et leurs dérivés utiles pour le traitement de maladies virales
|
WO2011068715A1
(fr)
|
2009-11-25 |
2011-06-09 |
Vertex Pharmaceuticals Incorporated |
Dérivés d'acide 5-alcynyl-thiophène-2-carboxylique et leur utilisation pour traiter ou prévenir des infections à flavivirus
|
JP2013514982A
(ja)
|
2009-12-18 |
2013-05-02 |
イデニク プハルマセウティカルス,インコーポレイテッド |
5,5−縮合アリーレン又はヘテロアリーレンc型肝炎ウイルス阻害剤
|
WO2011087740A1
(fr)
|
2009-12-22 |
2011-07-21 |
Schering Corporation |
Composés tricycliques fusionnés et leurs méthodes d'utilisation pour le traitement de maladies virales
|
NZ600786A
(en)
|
2009-12-22 |
2013-12-20 |
Cephalon Inc |
Proteasome inhibitors and processes for their preparation, purification and use
|
US20130072523A1
(en)
|
2009-12-24 |
2013-03-21 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
JP5833022B2
(ja)
|
2010-01-27 |
2015-12-16 |
エービー・ファーマ・リミテッド |
C型肝炎ウィルス阻害剤としてのポリ複素環式化合物
|
EP2536410B1
(fr)
|
2010-02-18 |
2015-09-23 |
Merck Sharp & Dohme Corp. |
Derives de pyrimidine substitues et leur utilisation dans le traitement d'infections virales
|
SG183843A1
(en)
|
2010-03-01 |
2012-10-30 |
Onyx Therapeutics Inc |
Compounds for immunoproteasome inhibition
|
WO2011112516A1
(fr)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Traitement et prévention de l'infection par le virus de l'hépatite c en utilisant des oligonucléotides antisens de la kinase c-raf
|
US8609635B2
(en)
|
2010-03-09 |
2013-12-17 |
Merck Sharp & Dohme Corp. |
Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
|
WO2011119853A1
(fr)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues pour traiter ou prévenir les infections à flavivirus
|
TW201141857A
(en)
|
2010-03-24 |
2011-12-01 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
CN103038237A
(zh)
|
2010-03-24 |
2013-04-10 |
沃泰克斯药物股份有限公司 |
用于黄病毒感染治疗或预防的类似物
|
WO2011119858A1
(fr)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues destinés au traitement ou à la prévention d'infections à flavivirus
|
KR101715981B1
(ko)
|
2010-03-31 |
2017-03-13 |
길리애드 파마셋 엘엘씨 |
뉴클레오사이드 포스포르아미데이트
|
US8680071B2
(en)
|
2010-04-01 |
2014-03-25 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
JP2013525282A
(ja)
|
2010-04-07 |
2013-06-20 |
オニキス セラピューティクス, インク. |
結晶質ペプチドエポキシケトンイムノプロテアソーム阻害剤
|
WO2011149856A1
(fr)
|
2010-05-24 |
2011-12-01 |
Presidio Pharmaceuticals, Inc. |
Inhibiteurs de ns5a du vhc
|
WO2011156545A1
(fr)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Modèle dynamique viral pour une polythérapie contre le vhc
|
US20130157258A1
(en)
|
2010-06-15 |
2013-06-20 |
Vertex Pharmaceuticals Incorporated |
Hcv ns5b protease mutants
|
MX2012014918A
(es)
|
2010-06-28 |
2013-04-08 |
Vertex Pharma |
Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
|
JP2013531011A
(ja)
|
2010-06-28 |
2013-08-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染の処置または予防のための化合物および方法
|
WO2012006070A1
(fr)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Composés et méthodes de traitement ou de prévention d'infections à flavivirus
|
EP2598149A4
(fr)
|
2010-07-26 |
2014-09-10 |
Merck Sharp & Dohme |
Composés de biphénylène substitué et procédés d'utilisation desdits composés pour le traitement de maladies virales
|
AR082619A1
(es)
|
2010-08-13 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores del virus de la hepatitis c
|
CN103153978A
(zh)
|
2010-08-17 |
2013-06-12 |
沃泰克斯药物股份有限公司 |
用于治疗或预防黄病毒科病毒感染的化合物和方法
|
AU2011314168A1
(en)
|
2010-09-29 |
2013-04-04 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
BR112013008510A2
(pt)
|
2010-10-08 |
2016-07-05 |
Novartis Ag |
vitamina e formulações de inibidores de sulfamida ns3
|
US8729014B2
(en)
|
2010-11-01 |
2014-05-20 |
Rfs Pharma, Llc |
Specific HCV NS3 protease inhibitors
|
AR084044A1
(es)
|
2010-11-30 |
2013-04-17 |
Pharmasset Inc |
Compuestos 2’-espiro-nucleosidos
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
WO2012107589A1
(fr)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc
|
WO2012123298A1
(fr)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Composés antiviraux
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
CN103842369A
(zh)
|
2011-03-31 |
2014-06-04 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10501493B2
(en)
|
2011-05-27 |
2019-12-10 |
Rqx Pharmaceuticals, Inc. |
Broad spectrum antibiotics
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2857705A1
(fr)
|
2011-06-16 |
2012-12-20 |
AB Pharma Ltd. |
Compose heterocyclique macrocyclique pour l'inhibition du virus de l'hepatite c, sa preparation et ses applications
|
CN103732242A
(zh)
|
2011-06-23 |
2014-04-16 |
迪格纳生物技术公司 |
用与IFN-α2b组合的IFN-α5在患者群体中治疗慢性丙型肝炎
|
WO2012175581A1
(fr)
|
2011-06-24 |
2012-12-27 |
F. Hoffmann-La Roche Ag |
Composés antiviraux
|
CN102807607B
(zh)
*
|
2011-07-22 |
2013-10-23 |
爱博新药研发(上海)有限公司 |
抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
|
WO2013016499A1
(fr)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Procédés de préparation de composés du thiophène
|
AR087344A1
(es)
|
2011-07-26 |
2014-03-19 |
Vertex Pharma |
Formas polimorficas del acido 5-(3,3-dimetil-but-1-inil)-3-[(trans-4-hidroxi-ciclohexil)-(trans-4-metil-ciclohexancarbonil)-amino]-tiofen-2-carboxilico y su uso en el tratamiento de la hepatitis c
|
WO2013033899A1
(fr)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Composés benzofuranes substitués et leur procédés d'utilisation pour le traitement de maladies virales
|
WO2013033900A1
(fr)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de maladies virales
|
WO2013033901A1
(fr)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales
|
US9403863B2
(en)
|
2011-09-12 |
2016-08-02 |
Idenix Pharmaceuticals Llc |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
CA2847892A1
(fr)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Composes et compositions pharmaceutiques pour le traitement d'infections virales
|
US20140378416A1
(en)
|
2011-09-14 |
2014-12-25 |
Michael P. Dwyer |
Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
|
JP5808496B2
(ja)
|
2011-10-10 |
2015-11-10 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗ウイルス化合物
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
US20130123276A1
(en)
|
2011-11-14 |
2013-05-16 |
Sven Ruf |
Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US9089574B2
(en)
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
WO2013086133A1
(fr)
|
2011-12-06 |
2013-06-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Méthodes et compositions pour le traitement de maladies virales
|
CN103987723B
(zh)
|
2011-12-16 |
2017-03-01 |
弗·哈夫曼-拉罗切有限公司 |
Hcv ns5a 的抑制剂
|
WO2013092481A1
(fr)
|
2011-12-20 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
|
CN108409820A
(zh)
|
2011-12-20 |
2018-08-17 |
里博科学有限责任公司 |
作为hcv rna复制抑制剂的4′-叠氮基,3′-氟取代的核苷衍生物
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
CN104039774A
(zh)
|
2012-01-12 |
2014-09-10 |
Rfs制药公司 |
Hcv ns3蛋白酶抑制剂
|
US20130217644A1
(en)
|
2012-02-13 |
2013-08-22 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
|
JP2015509942A
(ja)
*
|
2012-02-16 |
2015-04-02 |
アールキューエックス ファーマシューティカルズ,インク. |
直鎖ペプチド抗生物質
|
JP6092261B2
(ja)
*
|
2012-02-24 |
2017-03-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗ウイルス化合物
|
NZ630805A
(en)
|
2012-03-22 |
2016-01-29 |
Alios Biopharma Inc |
Pharmaceutical combinations comprising a thionucleotide analog
|
WO2013177188A1
(fr)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
|
WO2013177195A1
(fr)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
|
MD20140134A2
(ro)
|
2012-05-22 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
|
US20140010783A1
(en)
|
2012-07-06 |
2014-01-09 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
JP2015524394A
(ja)
|
2012-07-09 |
2015-08-24 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
|
WO2014053533A1
(fr)
|
2012-10-05 |
2014-04-10 |
Sanofi |
Utilisation de dérivés substitués de l'acide 3-hétéroaroylamino-propionique en tant que produits pharmaceutiques destinés à la prévention/au traitement de la fibrillation auriculaire
|
CN104936970A
(zh)
|
2012-10-08 |
2015-09-23 |
埃迪尼克斯医药公司 |
用于hcv感染的2′-氯核苷类似物
|
SI2909205T1
(sl)
|
2012-10-19 |
2017-02-28 |
Bristol-Myers Squibb Company |
9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
|
WO2014063019A1
(fr)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Composés dinucléotides contre une infection par le vhc
|
EP2909222B1
(fr)
|
2012-10-22 |
2021-05-26 |
Idenix Pharmaceuticals LLC |
Nucléosides 2', 4'-pontés pour l'infection par le vhc
|
US10260089B2
(en)
|
2012-10-29 |
2019-04-16 |
The Research Foundation Of The State University Of New York |
Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
|
WO2014071007A1
(fr)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014070964A1
(fr)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
EP2914614B1
(fr)
|
2012-11-05 |
2017-08-16 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
EP2920195A1
(fr)
|
2012-11-14 |
2015-09-23 |
IDENIX Pharmaceuticals, Inc. |
Ester de d-alanine d'analogue de rp-nucléoside
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
WO2014099941A1
(fr)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro-nucléosides pour le traitement du vhc
|
KR20150109451A
(ko)
|
2013-01-23 |
2015-10-01 |
에프. 호프만-라 로슈 아게 |
항바이러스성 트라이아졸 유도체
|
US20150065439A1
(en)
|
2013-02-28 |
2015-03-05 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
EP2970358B1
(fr)
|
2013-03-04 |
2021-06-30 |
Idenix Pharmaceuticals LLC |
3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
|
CN105008350B
(zh)
|
2013-03-05 |
2018-05-08 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒化合物
|
WO2014137869A1
(fr)
|
2013-03-07 |
2014-09-12 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
US20180200280A1
(en)
|
2013-05-16 |
2018-07-19 |
Riboscience Llc |
4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
|
US9895442B2
(en)
|
2013-05-16 |
2018-02-20 |
Riboscience Llc |
4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
|
EP2996696A4
(fr)
|
2013-05-16 |
2016-12-21 |
Riboscience Llc |
Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
|
WO2014197578A1
(fr)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
RU2016107436A
(ru)
*
|
2013-08-14 |
2017-09-19 |
АрКьюЭкс ФАРМАСЬЮТИКЛС, ИНК. |
Линейные пептидные антибиотики
|
PL3650014T3
(pl)
|
2013-08-27 |
2022-01-31 |
Gilead Pharmasset Llc |
Preparat złożony dwóch związków przeciwwirusowych
|
US20160229866A1
(en)
|
2013-09-20 |
2016-08-11 |
Idenix Pharmaceuticals Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(fr)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
|
EP3063140A4
(fr)
|
2013-10-30 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphes d'un inhibiteur de la protéine ns5a du vhc et leurs utilisations
|
US20160271162A1
(en)
|
2013-11-01 |
2016-09-22 |
Idenix Pharmacueticals, Llc |
D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
|
EP3074399A1
(fr)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
Analogues de nucléoside 2'-dichloro et 2'-fluoro-2'-chloro analogues pour l'infection par le vhc
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
EP2899207A1
(fr)
|
2014-01-28 |
2015-07-29 |
Amikana.Biologics |
Nouveau procédé pour tester l'inhibition de la protéase du HCV
|
WO2015134561A1
(fr)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Compositions pharmaceutiques comprenant un inhibiteur de flaviviridae hétéroarylène fusionné en 5,5 et son utilisation pour le traitement ou la prévention d'une infection par les flaviviridae
|
EP3113763A1
(fr)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Formes solides de promédicaments de 2'-chloro-2'-méthyl uridine pour lutter contre le vhc
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
WO2015161137A1
(fr)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
|
CA3005551A1
(fr)
|
2015-11-20 |
2017-05-26 |
Rqx Pharmaceuticals, Inc. |
Antibiotiques macrocycliques a large spectre
|
BR112018076614A2
(pt)
|
2016-06-21 |
2019-04-02 |
Orion Ophthalmology LLC |
derivados heterocíclicos de prolinamida
|
CN109563033B
(zh)
|
2016-06-21 |
2023-04-04 |
奥瑞恩眼科有限责任公司 |
脂族脯氨酰胺衍生物
|
EP3472151A4
(fr)
|
2016-06-21 |
2020-03-04 |
Orion Ophthalmology LLC |
Dérivés de prolinamide carbocycliques
|
EP3504193A1
(fr)
*
|
2016-08-23 |
2019-07-03 |
H. Hoffnabb-La Roche Ag |
Nouveaux dérivés de difluorocétamide en tant qu'inhibiteurs de htra1
|
JP6989864B2
(ja)
|
2017-05-05 |
2022-02-03 |
ジーランド ファーマ,アー/エス |
ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用
|
GB2563396B
(en)
|
2017-06-12 |
2020-09-23 |
Ustav Organicke Chemie A Biochemie Av Cr V V I |
Inhibitors of Rhomboid Intramembrane Proteases
|
CN111194217B
(zh)
|
2017-09-21 |
2024-01-12 |
里伯赛恩斯有限责任公司 |
作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物
|
KR20210098504A
(ko)
|
2018-12-04 |
2021-08-10 |
브리스톨-마이어스 스큅 컴퍼니 |
다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
|
US11208387B2
(en)
|
2019-05-28 |
2021-12-28 |
Genentech, Inc. |
Macrocyclic broad spectrum antibiotics
|